CYTOO Launches 2D+ Solutions at HCA
02 Jan 2013

CYTOO, a life science systems & tools company providing disruptive solutions for cell-based assays and High Content Screening (HCS), will launch the 2D+ Solutions at the High Content Analysis (HCA) Annual Meeting in San Francisco. CYTOO’s 2D+ Solutions open fresh perspectives for cell based assay development in drug discovery.

CYTOO’s 2D+ Cell Culture Platform is based on standard and custom adhesive micropatterns in 96-well plates to guide cell architecture and behavior in culture. By defining the 2D topology of cell adhesion, the 2D+ Cell Culture Platform enables fine control of the spreading and 3D shape of cultured cells in single- or multi-cellular configurations. This approach results in control of cell contractility, cell polarity, organelle positioning, and cell division axis. This technology addresses a major concern with traditional 2D culture, in which cells spread and move in an uncontrolled manner, introducing a considerable but unnoticed variability in cell function.

CYTOO’s Custom Solutions bring expertise, resources and technology to address current bottlenecks in cell based assay development and screening. 2D+ Custom Solutions begin with an in-depth analysis of the customer’s assay, by experienced PhD-level experts of the 2D+ technology.

The 2D+ Custom Solutions process includes: Exploratory solutions to guide customers through the initial exploration of the 2D+ technology; Assay development to select the best ecosystem for the requested cells; Screening to run small and medium screens.

Attendees are invited to visit HCA booth #24 to discuss their application with Pauline Poydenot, Head of Cell Assay Services, and Myles Fennell, Application Development Leader.

Request Info


Company website

CYTOO Inc.